(Q33588571)

28 July 2017

1 reference

title

Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism (English)

1 reference

28 July 2017

0 references

congestive heart failure

1 reference

Brunner-La Rocca HP

1

1 reference

28 July 2017

Vaddadi G

series ordinal

2

1 reference

28 July 2017

Esler MD

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

Journal of the American College of Cardiology

28 July 2017

published in

1 reference

28 July 2017

volume

33

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

1163-1173

1 reference

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Cardiac myocyte necrosis induced by angiotensin II

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Alternative pathways of angiotensin II production in the human saphenous vein

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II type 2 receptor mediates programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Mineralocorticoids, hypertension, and cardiac fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Determinants of angiotensin II generation during converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Chymase-dependent angiotensin II forming systems in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Myocardial fibrosis: functional significance and regulatory factors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

AT2 receptor blockade reduces cardiac interstitial cell DNA synthesis and cardiac function after rat myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Apoptosis in the failing human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Local application of angiotensin II to the rat carotid artery induces adventitial thickening

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: a link between angiotensin II and intimal thickening

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Kinin receptors in human vascular tissue: their role in atheromatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Quinaprilat Induces Arterial Vasodilation Mediated by Nitric Oxide in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Functional effects of endogenous bradykinin in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Valsartan in heart failure patients previously untreated with an ACE inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Role of the fibrinolytic system in preventing myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

The effect of bradykinin and substance P on the arachidonate cascade of platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

A bradykinin-antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

ACE inhibitor-induced angioedema. Incidence, prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Plasma bradykinin in angio-oedema.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Increased sensitivity to bradykinin among African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Increased vascular responsiveness to bradykinin in kidneys of spontaneously hypertensive rats. Effect of N omega-nitro-L-arginine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Evidence of a Selective Increase in Cardiac Sympathetic Activity in Patients with Sustained Ventricular Arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Adverse consequences of high sympathetic nervous activity in the failing human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II blockade [corrected] enhances baroreflex control of sympathetic outflow in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac beta-adrenergic signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Role of AT1 receptors in the central control of sympathetic vasomotor function.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

The AT2 receptor-mediated stimulation of adrenal catecholamine release may potentiate the AT1 receptor-mediated aldosterone secretagogue action of angiotensin-II in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Improving survival for patients with advanced heart failure: A study of 737 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Underutilization of evidence-based therapy in heart failure. An opportunity to deal a winning hand with ace up your sleeve

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Comparison of captopril and enalapril in patients with severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Practical issues when initiating captopril therapy in chronic heart failure. What is the appropriate dose and how long should patients be observed?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

The relationship between diuretic dose, and the haemodynamic response to captopril in patients with cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

ACE inhibitors and cough

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

Variations in cholesterol management practices of U.S. physicians.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900025-X

7 January 2021

10.1016/S0735-1097(99)00025-X

Identifiers

DOI

1 reference

28 July 2017

1 reference